April 20, 2015Open Access
View Full PaperBleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
Structured PICO
Does platelet reactivity assessment identify risk for mortality, stent thrombosis, and bleeding in PCI-treated patients on thienopyridine-type P2Y12-inhibitors?
P
Population
PCI-treated patients receiving thienopyridine-type P2Y12-inhibitors
I
Intervention
Platelet reactivity assessment
O
Outcome
Mortality, stent thrombosis (ST), and bleedinghard clinical
Platelet reactivity assessment can effectively stratify PCI patients on thienopyridines into high ischemic risk (HPR) or high bleeding risk (LPR) categories.
Abstract
Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).